Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727).
Holly ToveyOrsolya SiposJoel S ParkerKatherine A HoadleyJelmar QuistSarah KernaghanLucy Suzanne KilburnRoberto SalgadoSherene LoiRichard D KennedyIoannis RoxanisPatrycja GazinskaSarah E PinderJudith M BlissCharles M PerouSyed HaiderAnita GrigoriadisAndrew N J TuttMaggie Chon U CheangPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
High immune features predict docetaxel response, and high DDR signature scores predict carboplatin response in treatment-naïve mTNBC. Integrating multimodal DDR and immune-related markers identifies subgroups with differential treatment sensitivity. Treatment options for patients with immune-low and DDR-proficient tumors remains an outstanding need. Caution is needed using PT-derived transcriptional signatures to direct treatment in mTNBC, particularly DDR-related markers following prior chemotherapy.